Insider Selling: Stanley T. Crooke Unloads 16,000 Shares of ISIS Pharmaceuticals Stock (ISIS)

Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) CEO Stanley T. Crooke sold 16,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $30.53, for a total transaction of $488,480.00. Following the completion of the transaction, the chief executive officer now directly owns 6,941 shares in the company, valued at approximately $211,909. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) traded down 1.90% during mid-day trading on Friday, hitting $30.40. 1,445,586 shares of the company’s stock traded hands. ISIS Pharmaceuticals has a 52 week low of $22.25 and a 52 week high of $62.66. The stock’s 50-day moving average is $32.45 and its 200-day moving average is $38.23. The company’s market cap is $3.574 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.04. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $35.12 million. During the same quarter last year, the company posted ($0.02) earnings per share. ISIS Pharmaceuticals’s revenue was down 35.0% compared to the same quarter last year. On average, analysts predict that ISIS Pharmaceuticals will post $-0.71 earnings per share for the current fiscal year.

A number of research firms have recently commented on ISIS. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, June 5th. They now have a $29.00 price target on the stock. Separately, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Finally, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. ISIS Pharmaceuticals has an average rating of “Hold” and an average target price of $41.10.

Receive News & Ratings for ISIS Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ISIS Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Traders Buy High Volume of Anadarko Petroleum Call Options
Traders Buy High Volume of Anadarko Petroleum Call Options
Marathon Petroleum Corp Now Covered by Analysts at RBC Capital
Marathon Petroleum Corp Now Covered by Analysts at RBC Capital
Tesoro Coverage Initiated at RBC Capital
Tesoro Coverage Initiated at RBC Capital
salesforce.com, inc. Earns Neutral Rating from Analysts at DA Davidson
salesforce.com, inc. Earns Neutral Rating from Analysts at DA Davidson
Interval Leisure Group Reaches New 1-Year Low at $18.86
Interval Leisure Group Reaches New 1-Year Low at $18.86
STAAR Surgical Company Reaches New 12-Month Low at $10.07
STAAR Surgical Company Reaches New 12-Month Low at $10.07


Leave a Reply

 
© 2006-2014 Mideast Time.